Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Curr Opin Urol. 2016 Sep;26(5):472–480. doi: 10.1097/MOU.0000000000000310

Table 2.

Risk of prostate cancer on fusion biopsy based on mpMRI findings in biopsy naïve patients. (10)

Systematic Plus Targeted
Maximum ROI grade Negative GS 3+3=6 GS 3+4=7 GS ≥ 4+3=7
No lesion/grade 1-2 38 (68%) 11 (20%) 4 (7%) 3 (5%)
Grade 3 60 (46%) 27 (21%) 32 (25%) 10 (8%)
Grade 4 36 (33%) 28 (26%) 21 (19%) 24 (22%)
Grade 5 1 (3%) 5 (14%) 8 (23%) 21 (60%)